BMO Capital maintains Alnylam Pharmaceuticals at Outperform, raises price target to $293 from $292
BMO Capital has reiterated its Outperform rating for Alnylam Pharmaceuticals (ALNY) and slightly increased its price target from $292 to $293, suggesting a 98.2% upside from its November 19th closing price. This comes amid other recent analyst actions, with price targets ranging from $205 to $380 over the past 30 days.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) due to potential securities fraud or unlawful business practices. This investigation follows Alnylam's report on October 29, 2026, which indicated slowing demand for its transthyretin-mediated amyloidosis treatment, Amvuttra, leading to a significant drop in the company's stock price. Investors are encouraged to contact Pomerantz LLP for more information regarding joining the class action.
Alnylam Pharmaceuticals stock hits 52-week low at 149.17 USD
Alnylam Pharmaceuticals (ALNY) stock has dropped to a new 52-week low of $149.17, reflecting a significant 67.59% decline over the past year. Despite the downturn, InvestingPro analysis suggests the stock may be undervalued. The company recently announced a $1 billion stock repurchase program, the departure of its Chief Commercialization Officer, and slight misses on Q3 Amvuttra sales, leading to lowered price targets from several analysts.
JPMorgan cuts Alnylam stock price target on Amvuttra forecast
JPMorgan has reduced its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) shares from $369 to $254, while maintaining an Overweight rating, due to lowered Amvuttra revenue forecasts for 2026-2030. This adjustment comes as Alnylam shares have significantly declined year-to-date, contrasting with gains in broader market indices, following multiple expectation resets for Amvuttra and uncertainties regarding reimbursement changes. Other analysts have also lowered their price targets, despite Alnylam announcing a $1 billion stock repurchase program.
Alnylam Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $283.79, Implies 81% Upside
Alnylam Pharmaceuticals, Inc. (ALNY) has seen its average 12-month price target cut slightly from $286.4 to $283.79 by 24 analysts, with individual forecasts ranging from $180 to $410 per share. This updated target suggests an 81% potential upside based on the stock's closing price on November 17. The consensus rating for ALNY remains a "Buy" from 29 analysts.
Did Alnylam Pharmaceuticals' 64% Drop Catch You Out? What Bears Saw
Alnylam Pharmaceuticals experienced a significant 64.2% loss over the past year, leading to investor scrutiny regarding RNAi growth, TTR concentration risk, and pricing pressure. While Q3 2026 results showed strong revenue and net income, a subsequent cut to 2026 TTR guidance and legal investigations complicated the outlook. The company now trades at US$165, with analysts considering whether AMVUTTRA's access and execution in broader indications can justify the RNAi story at this new price.
Arexera Says Huntington's Drug ATL-101 Cut Huntingtin Up to 80% in Primates; Alnylam Has Human Data
Arexera Therapeutics announced that its Huntington's disease drug ATL-101 reduced huntingtin protein by up to 80% in non-human primate brain tissue and that China approved a Phase 1 trial. This primate data is company-reported and will be presented in 2027. While a promising biomarker, the results are from primate tissue and cannot be directly compared to Alnylam's human spinal fluid data for its rival drug, brezosiran, which showed a 60% to 64% average drop in patients.
T. Rowe Price reports 10,017,904 Alnylam (ALNY) shares in a passive stake.
T. Rowe Price Investment Management, Inc. has reported a 7.5% passive stake in Alnylam Pharmaceuticals, Inc. (ALNY), holding 10,017,904 shares as of September 30, 2026. The filing, a Schedule 13G, indicates T. Rowe Price has sole voting power over 9,530,952 shares and sole dispositive power over all 10,017,904 shares. The firm, however, explicitly denies that the statement should be construed as an admission of beneficial ownership.
One investor reports owning 10.9 million shares of Alnylam (ALNY).
Capital Research Global Investors has filed an amended beneficial-ownership report for Alnylam Pharmaceuticals, Inc. (ALNY), indicating ownership of 10,940,905 common shares, which represents 8.2% of the company's believed outstanding shares. The report details sole voting power over 10,922,799 shares and sole dispositive power over 10,940,905 shares, with no shared voting or dispositive power. This disclosure provides transparency on the significant passive investment by Capital Research Global Investors in Alnylam.
Alnylam Pharmaceuticals shares jump around 5.5% as strong Q3 product revenue drives commercial momentum
Alnylam Pharmaceuticals (ALNY) shares rose 5.4% after reporting strong third-quarter product revenue of $1.29 billion, a 52% year-over-year increase, primarily driven by AMVUTTRA sales. Despite this rebound, the stock remains below key moving averages, indicating persistent bearish pressure due to concerns over slower patient adoption and reimbursement challenges. Analysts suggest rallies are likely to fade unless the price reclaims $167.99 with strong volume, and caution is warranted for traders.
An investment manager reports over 10% of Alnylam (ALNY), with no shared voting power.
Capital World Investors reported a beneficial ownership of 13,934,539 shares, representing 10.4% of Alnylam Pharmaceuticals, Inc. (ALNY) common stock, as of September 30, 2026. The investment manager maintains sole voting power over 13,889,698 shares and sole dispositive power over 13,934,539 shares, with no shared voting or dispositive power reported. This filing was made under Schedule 13G/A, indicating a passive investment.
What Moved Alnylam Stock?
Alnylam Pharmaceuticals (ALNY) stock rose 5.4% on Wednesday, November 11, 2026, while the broader S&P 500 gained 1.3%. This surge occurred despite the company not reporting earnings and followed a significant drop earlier due to management's dissatisfaction with demand growth and lower sales expectations for its TTR drugs. The gain helped Alnylam recover from a year-low, aligning with a wider market rally driven by eased worries about AI profits, though it still faces a substantial year-over-year decline.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
Pomerantz LLP is investigating Alnylam Pharmaceuticals, Inc. for potential securities fraud or unlawful business practices after the company reported slowing demand for its Amvuttra treatment, which significantly impacted its stock price. The investigation follows Alnylam's third-quarter financial results for 2026, where a notable decrease in transthyretin demand growth was announced. This news led to a 25.13% drop in Alnylam's stock on October 29, 2026.
Alnylam Pharmaceuticals (ALNY) Is Up 5.4% What’s Changed After Five Year Drug Data
Alnylam Pharmaceuticals reported positive five-year HELIOS-B data for its drug AMVUTTRA, showing improved outcomes for patients with transthyretin amyloidosis with cardiomyopathy. This strengthens the investment narrative around AMVUTTRA as a key product, aligning with the company's reiterated 2026 revenue guidance and a recent US$1.0b share repurchase authorization. Despite ongoing execution risks, the company's long-term outlook projects significant revenue and earnings growth by 2029.
Stock Watch: Lilly’s 52-Week High Meets Alnylam’s 52-Week Low
Eli Lilly's stock reached a 52-week high after announcing strong third-quarter growth driven by its GLP-1 agonists Mounjaro and Zepbound. In stark contrast, Alnylam Pharmaceuticals' stock hit a 52-week low on the same day as it reported its third-quarter results. Both companies are heavily reliant on dominant franchises, with Lilly's success attributed to its diabetes and obesity drugs, while Alnylam faced challenges.
Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
Alnylam Pharmaceuticals announced five-year HELIOS-B data at the American Heart Association (AHA) Scientific Sessions 2026, demonstrating that continuous treatment with AMVUTTRA (vutrisiran) provides sustained benefits for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Patients treated continuously with AMVUTTRA showed lower rates of mortality and cardiovascular events, better quality of life, and greater stability of cardiac biomarkers compared to those with delayed treatment initiation. A separate analysis also indicated that AMVUTTRA preserved exercise capacity and cardiopulmonary function.
Weekly Recap: $1 billion buyback authorized and Truist downgrades to Hold
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) authorized a share buyback of up to $1 billion, with plans to repurchase $500 million by year-end 2026 and the rest in 2027. Truist Securities downgraded Alnylam to Hold from Buy, lowering its price target to $225 from $315. Additionally, Alnylam announced that Chief Commercialization Officer Tolga Tanguler will depart in December 2026 and will present new AMVUTTRA data at November 2026 medical meetings.
Alnylam Pharmaceuticals (ALNY) Faces A Valuation Test After Fresh AMVUTTRA Data
Alnylam Pharmaceuticals recently presented new clinical and real-world data for AMVUTTRA, but despite this and a solid Q3 update, the stock has fallen significantly. The market currently views ALNY as 53% undervalued with a fair value of $331.22, though potential risks like pricing pressure for AMVUTTRA could quickly change this outlook. Investors are now assessing whether the stock's decline is due to business problems or a shift in sentiment.
We Believe Alnylam Pharmaceuticals' (NASDAQ:ALNY) Earnings Are A Poor Guide For Its Profitability
Alnylam Pharmaceuticals' recent earnings disappointed investors due to weak underlying factors, specifically a high accrual ratio of 1.33, indicating that free cash flow is significantly weaker than its reported profit. The company also benefited from an unusual $1.9 billion tax benefit which temporarily boosted statutory profit and contributed to the poor accrual ratio, suggesting that future profitability may be overstated if this benefit is not repeated. These factors lead to skepticism regarding Alnylam's sustainable earnings power.
Alnylam Pharmaceuticals stock hits 52-week low at $155.22
Alnylam Pharmaceuticals (ALNY) stock has dropped to a 52-week low of $155.22, significantly down from its high of $479.79, marking a 64.61% decrease over the past year. Despite the downturn, InvestingPro analysis suggests the stock is undervalued with a Fair Value of $198.85 and is in oversold territory based on its RSI. The company recently announced a $1 billion stock repurchase program and changes in executive leadership, while several financial firms have lowered their price targets due to execution risks and slower demand growth for its AMVUTTRA product.
Why Alnylam Pharmaceuticals Bears Were Right Before A 65% Drop
Alnylam Pharmaceuticals shareholders experienced a 64.6% loss over the past year, proving the bearish narrative regarding the company's stock to be accurate. The article analyzes the Q3 2026 report, which showed strong revenue and net income, supporting the profitability aspect of the optimistic case, but notes that the stock now trades significantly lower than its initial price, aligning with the concerns of pricing pressure and high R&D spending.
Alnylam Pharmaceuticals announces $1 billion stock repurchase program and executive departure
Alnylam Pharmaceuticals (NASDAQ:ALNY) has announced a $1 billion stock repurchase program, with $500 million expected to be repurchased by the end of 2026 and the remainder in 2027. The company also disclosed the departure of Tolga Tanguler, Executive Vice President and Chief Commercialization Officer, in December 2026. These developments follow recent analyst adjustments to price targets and ratings, driven by the company's third-quarter revenue and full-year guidance for its TTR franchise.
Form 8K Alnylam Pharmaceuticals Inc For: 5 November By Investing.com
Alnylam Pharmaceuticals Inc. filed a Form 8K for November 5th. The article, published by Investing.com, indicates this financial filing is publicly available information, likely detailing significant events or changes within the company.
Top 3 Health Care Stocks You'll Regret Missing In Q4
This article identifies three healthcare stocks—Alnylam Pharmaceuticals (ALNY), Madrigal Pharmaceuticals (MDGL), and Corcept Therapeutics (CORT)—that are currently oversold, indicating a potential buying opportunity for investors in Q4. Each company has experienced a recent stock decline, placing their Relative Strength Index (RSI) near or below 30, a key indicator for oversold assets. The article highlights recent company announcements and financial performance, suggesting these stocks may be undervalued.
Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference 2026
Alnylam Pharmaceuticals announced that its management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT in London. A live audio webcast of the presentation will be available on the Investors section of the Company’s website, with a replay posted within 48 hours after the event. Alnylam is a leading RNAi therapeutics company developing transformative therapies and executing its "Alnylam 2030" strategy.
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
Alnylam Pharmaceuticals announced a $1 billion share repurchase program, demonstrating confidence in its long-term growth and commitment to disciplined capital allocation. The company also announced a transition in its commercial leadership with Tolga Tanguler departing as Chief Commercialization Officer, as Alnylam enters its next phase of growth and aims to expand the reach of its medicines.
Alnylam authorizes $1 billion share buyback program
Alnylam Pharmaceuticals, Inc. has announced a $1 billion share repurchase program, reflecting confidence in its future growth and perceived undervaluation of its stock. The company plans to execute half of the buyback by the end of 2026 and the rest in 2027. Additionally, Alnylam disclosed the departure of its Chief Commercialization Officer and is actively seeking a replacement.
Alnylam Pharmaceuticals authorizes $1B share repurchase program
Alnylam Pharmaceuticals' board has approved a $1 billion share repurchase program. The company intends to buy back approximately $500 million worth of shares by the end of 2026, with the remaining $500 million planned for 2027. This move is expected to return capital to shareholders.
Can Alnylam Pharmaceuticals (ALNY) Justify Its Price After A 62% Fall?
Alnylam Pharmaceuticals (ALNY) has seen a significant 62.3% share price drop over the past year, prompting questions about its current valuation. Despite recent strong Q3 2026 earnings and active RNA interference programs, the stock trades at a P/E ratio of 8.1x, well below sector and peer averages, suggesting it may be undervalued. The article explores whether the company's underlying earnings power and future growth prospects can justify its current price.
Form 4 Alnylam Pharmaceuticals Inc For: 2 November By Investing.com
This article from Investing.com announces the filing of Form 4 by Alnylam Pharmaceuticals Inc. for November 2. It appears to be a basic notification of an insider transaction document, without providing further details in the body of the article. The content primarily consists of navigational elements and market data, rather than a detailed report on the Form 4 itself.
Barclays maintains Alnylam Pharmaceuticals at Overweight, lowers price target to $380 from $450
Barclays has reiterated its Overweight rating for Alnylam Pharmaceuticals but reduced its price target from $450 to $380, representing a 15.6% decrease. This new price target implies a significant upside of 158.2% from the stock's closing price on October 30. Other analysts have recently issued ratings and price targets for Alnylam Pharmaceuticals, with targets ranging from $199 to $354.
Should You Buy The Dip In Alnylam Stock?
Alnylam Pharmaceuticals (ALNY) stock recently dropped significantly after its Q3 2026 earnings report, due to management's concerns about demand growth. Historically, similar drops in Alnylam's stock have led to higher prices a year later less than half the time, with mixed results. The company is still growing drug sales and generating cash, but its short-term outlook is impacted by slower patient starts and potential hospital ordering caution due to the 340B drug discount program.
Form 4 Alnylam Pharmaceuticals Inc For: 2 November By Investing.com
This article announces the filing of Form 4 for Alnylam Pharmaceuticals Inc. on November 2, 2026. The filing is a standard regulatory disclosure related to insider transactions. The article provides minimal detail beyond the announcement itself.
Alnylam Pharmaceuticals, Inc. (ALNY) Stock forecasts
Alnylam Pharmaceuticals, Inc. (ALNY) is a leader in RNA interference (RNAi) therapeutics, with its commercial products reviewed in a recent analyst report. The report from Morningstar notes strong revenue growth but highlights slower-than-expected demand for TTR, impacting the company's performance. The stock's current price is $158.00.
Alnylam Pharmaceuticals stock hits 52-week low at $187.12
Alnylam Pharmaceuticals (ALNY) stock recently hit a 52-week low, currently trading at $180.65, representing a 51.74% decrease over the past year. Despite the downturn, InvestingPro data suggests the stock is undervalued with a PEG ratio of 0.11, indicating strong growth potential. The company, which focuses on RNA interference therapeutics, has seen a 95% revenue surge over the last twelve months and anticipates net income growth this year, with analysts reiterating "Strong Buy" and "Buy" ratings based on positive trial results for brezosiran and zilebesiran.
Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
Alnylam Pharmaceuticals reported strong third-quarter 2026 financial results, with global net product revenues of $1,292 million, a 52% increase year-over-year, driven primarily by its TTR franchise (AMVUTTRA and ONPATTRO). The company also announced expanded enrollment for its TRITON-CM Phase 3 study of nucresiran for ATTR-CM, and positive Phase 1 data for brezosiran in Huntington's disease, with a pivotal study expected in 2027. Alnylam reiterated its full-year 2026 financial guidance, anticipating continued growth across its product portfolio and pipeline advancements.
Alnylam Pharmaceuticals Q3 2026 Earnings Call Transcript
Alnylam Pharmaceuticals reported a 52% year-over-year increase in Q3 2026 product revenues, reaching $1.3 billion, primarily driven by Amvuttra. While the company is expanding its prescriber base, the translation of increased physician engagement into patient starts is slower than anticipated, leading to an expectation of landing at the low end of its 2026 TTR product sales guidance of $4.2 billion to $4.5 billion. Alnylam is also expanding enrollment for its Triton CM study for nucrisiran and advancing a pivotal study for brazosiran in Huntington's disease, reiterating its long-term growth confidence despite potential challenges from a proposed CMS 340B rule change.
How Early Huntington's Trial Results Will Impact Alnylam Stock
Alnylam Pharmaceuticals reported initial Phase 1b data for brezosiran in Huntington’s disease, showing significant, dose-dependent reductions in mutant huntingtin and an encouraging safety profile, with potential for a twice-yearly dosing schedule. While the early results suggest target engagement, functional benefit is yet to be confirmed. The company's investment narrative continues to lean on its TTR franchise and late-stage programs, with this Huntington's update adding a longer-term milestone.
UBS cuts target for Alnylam Pharmaceuticals stock from USD 550.00 to USD 354.00
UBS has lowered its price target for Alnylam Pharmaceuticals from USD 550.00 to USD 354.00, while maintaining a Buy rating. This adjustment follows the release of initial Phase 1b data for brezosiran in Huntington's disease, which showed a significant reduction in mutant huntingtin. Alnylam Pharmaceuticals is scheduled to report its third-quarter 2026 financial results on October 29, 2026, which will be a key event for investors.
Citi Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $320
Citi has reiterated its Buy rating on Alnylam Pharmaceuticals (ALNY.US) and maintained its target price of $320. This indicates a continued positive outlook from the firm regarding Alnylam's stock performance and future prospects.
Alnylam Lobbying Rises Amid Medicare Drug Pricing Debate
Alnylam Pharmaceuticals Inc. has increased its lobbying efforts, spending $730,000 in Q3, focusing on Medicare home infusion coverage, the Inflation Reduction Act, most-favored-nation drug pricing, and pharmaceutical supply chain tariffs. The company is particularly engaged with H.R. 1672, the Maintaining Investments in New Innovation Act, which seeks to extend the period before genetically targeted therapies become eligible for Medicare price negotiation. These lobbying activities reflect ongoing debates in Congress and the administration over policies impacting prescription drug coverage and pricing.
Alnylam Pharmaceuticals, Inc. Estimates – NASDAQ:ALNY
The article provides an overview of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) financial estimates on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform also enables comparison of actual results with average, high, and low estimates, alongside visualization of trends over time.
Alnylam Pharmaceuticals (ALNY) Cuts 2026 Guidance After AMVUTTRA Sales Beat, Is It Fully Valued
Alnylam Pharmaceuticals (ALNY) recently lowered its full-year 2026 revenue guidance despite strong AMVUTTRA sales, causing a significant drop in its share price. While many view the company as undervalued, citing its extensive RNAi pipeline and potential new product cycles, its high P/E ratio compared to the industry suggests a less clear-cut valuation. Investors are urged to consider both the perceived undervaluation and the risks associated with pricing pressure or R&D spending.
Is Lower AMVUTTRA Guidance Altering The Investment Case For Alnylam Stock?
Alnylam Pharmaceuticals (NASDAQ:ALNY) recently reported strong AMVUTTRA revenue but cut full-year guidance due to demand normalization and increased competition. Despite the revised outlook, the company is now generating significant revenue and net income, shifting its narrative from a pure pipeline story to a profitable business with potential S&P 500 eligibility. The investment case now centers on management's ability to execute on pricing and market access for AMVUTTRA, alongside the potential of its broader RNAi pipeline.
Wells Fargo cuts Alnylam target to USD 253 for Alnylam Pharmaceuticals stock
Wells Fargo has lowered its price target for Alnylam Pharmaceuticals (ALNY) stock to $253.00 from $256.00, while maintaining an "Equal Weight" rating. This adjustment comes despite the biotechnology company reporting strong second-quarter revenue and earnings per share that exceeded consensus estimates. Alnylam Pharmaceuticals is set to release its third-quarter results on October 29, 2026.
BofA cuts target to USD 336.00 for Alnylam Pharmaceuticals stock
BofA has reduced its price target for Alnylam Pharmaceuticals (ALNY) to USD 336.00 from USD 346.00, while maintaining a Buy rating. This adjustment reflects a more conservative outlook on the long-term growth in the ATTR-CM market. Alnylam Pharmaceuticals is scheduled to report its third-quarter 2026 results on October 29, 2026.
What Has Changed For Alnylam Pharmaceuticals Since Its 52% Fall
Alnylam Pharmaceuticals (NASDAQ: ALNY) has seen a 52% fall in its stock price over the past year, prompting a re-evaluation of its prospects. While the company has shown a shift towards profitability with Q2 2026 net margin at 12.7%, concerns remain regarding TTR sales guidance cuts and regulatory risks. The current valuation suggests that investors are weighing the potential of its broad RNAi portfolio, including pivotal programs like zilebesiran, against these challenges, moving beyond the sole reliance on the TTR franchise.
Alnylam founder's new biotech lands $200M in upsized IPO
City Therapeutics, a new biotech company founded by Alnylam executive chair John Maraganore, successfully completed an upsized IPO, raising $200 million. The company had previously secured nearly $235 million in venture capital before its public debut. Andy Orth serves as the CEO of City Therapeutics.
Alnylam Pharmaceuticals Is Maintained at Buy by Citigroup
Citigroup has reaffirmed its Buy rating on Alnylam Pharmaceuticals. This indicates the firm's continued confidence in the company's stock performance.
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced it will report its third-quarter 2026 financial results on Thursday, October 29, 2026, before market open. The company will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a company update. An archived webcast will be available on Alnylam's investor relations website.